OTCM
FZMD
Market cap2mUSD
Oct 08, Last price
0.03USD
1D
-9.09%
1Q
2.56%
Jan 2017
-81.25%
Name
Fuse Medical Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Richardson, Texas, Fuse Medical, Inc. operates as a U.S.-based manufacturer and supplier of medical device implants. Its product portfolio primarily encompasses a wide range of orthopedic implants. This includes specialized internal and external fixation devices for the foot and ankle, as well as plating systems and total joint reconstruction implants designed for upper and lower extremities. Additionally, Fuse Medical provides solutions for soft tissue fixation and augmentation, catering to sports medicine procedures. The company's offerings extend to comprehensive spinal implants, addressing indications such as trauma, degenerative disc disease, and various deformities. Beyond its orthopedic line, the company also supplies osteo-biologics and regenerative products. These encompass a variety of materials such as human allografts, tendons, synthetic skin, bone substitutes, and other regenerative tissues. Fuse Medical's client base includes hospitals, diverse medical facilities, and a network of sub-distributors.
Key people
Mark Brooks
Chairman of the Board, President, Director · since 2018
Christopher Reeg
Chief Executive Officer, Secretary, Director · since 2018
Lawrence Yellin
Chief Financial Officer, Treasurer, Director · since 2022
Renato Bosita
Independent Director · since 2017
Legal address
C/O CAPITOL SERVICES, INC.
108 LAKELAND AVE.
DOVER, DE 19901
US
108 LAKELAND AVE.
DOVER, DE 19901
US
Headquarters
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Previous name
Golf Rounds.com, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||